Pancreatic Cancer
Erlotinib tolerated in patients with locally advanced pancreatic cancer
Published in Cancer Weekly, February 21st, 2006
According to recent research from the United States, "A phase I trial was conducted to determine the maximally tolerated dose of erlotinib with concurrent gemcitabine, paclitaxel, and radiation for patients with locally advanced pancreatic cancer and to gather preliminary data on maintenance erlotinib after chemoradiation. Patients received gemcitabine, 75 mg/m2, and paclitaxel, 40 mg/m2, weekly for 6 weeks with 50.4 radiation to the primary tumor and draining lymph nodes with a 2- to 3-cm margin. Erlotinib was administered over 3-dose levels (50-100 mg/d) with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-02-21)
More Articles from Cancer Weekly
- Brain Cancer
TWIST is expressed in human gliomas and promotes invasion - Cancer Drugs
Doxorubicin-induced cardiotoxicity could be prevented by melatonin - Colorectal Metastases
Recent chemotherapy reduced sensitivity of FDG-PET in detecting colorectal metastases - Lung Cancer
JNK activation required for gemcitabine's cytotoxic effect in lung cancer - Pituitary Tumors
Mimecan gene expression used as a marker for diagnosing pituitary tumors - Acute Myeloid Leukemia
Modified conventional protocol for childhood AML well tolerated - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
